Positive Phase I/II Study Results for AMT-130
uniQure N.V. (NASDAQ: QURE), a pioneering gene therapy company focused on serious medical needs, has reported encouraging topline data from the pivotal Phase I/II study of AMT-130 for Huntington’s disease. This crucial research highlighted a remarkable 75% slowing of disease progression over 36 months, as noted in the composite Unified Huntington’s Disease Rating Scale (cUHDRS).
Key Study Findings
The pivotal study successfully met its designated primary endpoint. The high-dose group of AMT-130 demonstrated a statistically significant reduction in disease progression compared to a carefully matched external control group. Alongside the primary endpoint, significant results were observed in secondary measures such as Total Functional Capacity (TFC), which also showed noteworthy disease progression slowing.
Insights from Experts
Sarah Tabrizi, M.D., a prominent figure in neurology and director at the University College London Huntington’s Disease Center, expressed her excitement over the findings. She noted that these results are groundbreaking and highlight the potential of AMT-130 to meaningfully alter the course of Huntington’s disease, providing hope to affected families.
Statistical Outcomes
Among the key findings of the study, the high-dose AMT-130 group exhibited the following results, as of the June 30, 2025 data cutoff:
- 75% slowing of disease progression as per cUHDRS (p=0.003).
- 60% slowing of disease progression by TFC (p=0.033).
- A mean decrease in the cerebrospinal neurofilament light protein (CSF NfL) levels, an essential biomarker of neurodegeneration, indicating a decrease by 8.2%.
Long-Term Efficacy
The company believes that the robust performance in the high-dose group reinforces a dose-dependent response. Key secondary endpoints related to motor and cognitive function also displayed positive trends, although some results are still under observation.
Safety Profile
AMT-130 was well-tolerated across both dosing groups, maintaining a manageable safety profile. Since December 2022, no new serious adverse events linked to the drug have been reported. Any common side effects were procedural and resolved swiftly.
Future Plans for AMT-130
uniQure is making strides towards regulatory submission, with plans to submit a Biologics License Application (BLA) in the first quarter of 2026. The expected launch in the U.S. will depend upon regulatory approvals. The news of this application sparks optimism within the Huntington’s disease community, heralding a potential shift in treatment methodologies.
Investing in the Future
Walid Abi-Saab, M.D., the chief medical officer of uniQure, expressed enthusiasm regarding the results from the study. He indicated that these findings represent a transformative possibility for Huntington’s disease and reflect the dedication of the entire uniQure team along with collaborators, patients, and their families.
About AMT-130
AMT-130 exemplifies the advancements in gene therapy, designed to provide comprehensive solutions for patients grappling with Huntington’s disease and other severe conditions. By utilizing a one-time, precision-delivered approach, uniQure is paving the way for innovative treatments that can potentially reshape the future of neurological disorder therapies.
Frequently Asked Questions
What are the primary results of the AMT-130 study?
The study found a 75% slowing of disease progression among high-dose AMT-130 patients measured over 36 months.
Who is involved in the AMT-130 clinical research?
uniQure, led by prominent researchers and medical professionals, is conducting the Phase I/II studies, collaborating with various clinical centers.
How does AMT-130 affect Huntington’s disease?
AMT-130 targets disease progression with the potential to slow symptoms and improve quality of life for patients dealing with Huntington’s disease.
What safety profile does AMT-130 exhibit?
The treatment has shown to be generally well-tolerated, with minimal adverse events reported.
What are the future plans for AMT-130?
uniQure aims to submit a BLA for AMT-130 in 2026 and hopes to launch in the U.S. pending regulatory approval.
